Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging

Mirella L. Altoe; Alessandro Marone; Hyun K. Kim; Mariella Tejada; Hanina Hibshoosh; Hua Guo; Katherine D. Crew; Melissa K. Accordino; Meghna Trivedi; Kevin Kalinsky; Dawn L. Hershman; Andreas H. Hielscher

doi:10.1364/OTS.2020.SM2D.2

Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging

Mirella L. Altoe, Alessandro Marone, Hyun K. Kim, Mariella Tejada, Hanina Hibshoosh, Hua Guo, Katherine D. Crew, Melissa K. Accordino, Meghna Trivedi, Kevin Kalinsky, Dawn L. Hershman, Andreas H. Hielscher

Biomedical Engineering

Research output: Contribution to conference › Abstract

Abstract

Normalized ctTHb levels measured prior to neoadjuvant chemotherapy can predict breast cancer response to NAC and potentially be used to improve personalized therapeutic strategies for HER-2 positive tumors.

Original language	English (US)
DOIs	https://doi.org/10.1364/OTS.2020.SM2D.2
State	Published - 2020
Event	Optical Tomography and Spectroscopy, OTS 2020 - Washington, United States Duration: Apr 20 2020 → Apr 23 2020

Conference

Conference	Optical Tomography and Spectroscopy, OTS 2020
Country/Territory	United States
City	Washington
Period	4/20/20 → 4/23/20

ASJC Scopus subject areas

Mechanics of Materials
Electronic, Optical and Magnetic Materials

Access to Document

10.1364/OTS.2020.SM2D.2

Cite this

Altoe, M. L., Marone, A., Kim, H. K., Tejada, M., Hibshoosh, H., Guo, H., Crew, K. D., Accordino, M. K., Trivedi, M., Kalinsky, K., Hershman, D. L., & Hielscher, A. H. (2020). Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging. Abstract from Optical Tomography and Spectroscopy, OTS 2020, Washington, United States. https://doi.org/10.1364/OTS.2020.SM2D.2

Altoe, ML, Marone, A, Kim, HK, Tejada, M, Hibshoosh, H, Guo, H, Crew, KD, Accordino, MK, Trivedi, M, Kalinsky, K, Hershman, DL & Hielscher, AH 2020, 'Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging', Optical Tomography and Spectroscopy, OTS 2020, Washington, United States, 4/20/20 - 4/23/20. https://doi.org/10.1364/OTS.2020.SM2D.2

@conference{2129fea7c281422798f66a907911e0f6,

title = "Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging",

abstract = "Normalized ctTHb levels measured prior to neoadjuvant chemotherapy can predict breast cancer response to NAC and potentially be used to improve personalized therapeutic strategies for HER-2 positive tumors.",

author = "Altoe, {Mirella L.} and Alessandro Marone and Kim, {Hyun K.} and Mariella Tejada and Hanina Hibshoosh and Hua Guo and Crew, {Katherine D.} and Accordino, {Melissa K.} and Meghna Trivedi and Kevin Kalinsky and Hershman, {Dawn L.} and Hielscher, {Andreas H.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).; Optical Tomography and Spectroscopy, OTS 2020 ; Conference date: 20-04-2020 Through 23-04-2020",

year = "2020",

doi = "10.1364/OTS.2020.SM2D.2",

language = "English (US)",

}

TY - CONF

T1 - Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging

AU - Altoe, Mirella L.

AU - Marone, Alessandro

AU - Kim, Hyun K.

AU - Tejada, Mariella

AU - Hibshoosh, Hanina

AU - Guo, Hua

AU - Crew, Katherine D.

AU - Accordino, Melissa K.

AU - Trivedi, Meghna

AU - Kalinsky, Kevin

AU - Hershman, Dawn L.

AU - Hielscher, Andreas H.

PY - 2020

Y1 - 2020

N2 - Normalized ctTHb levels measured prior to neoadjuvant chemotherapy can predict breast cancer response to NAC and potentially be used to improve personalized therapeutic strategies for HER-2 positive tumors.

AB - Normalized ctTHb levels measured prior to neoadjuvant chemotherapy can predict breast cancer response to NAC and potentially be used to improve personalized therapeutic strategies for HER-2 positive tumors.

UR - http://www.scopus.com/inward/record.url?scp=85091399407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091399407&partnerID=8YFLogxK

U2 - 10.1364/OTS.2020.SM2D.2

DO - 10.1364/OTS.2020.SM2D.2

M3 - Abstract

AN - SCOPUS:85091399407

T2 - Optical Tomography and Spectroscopy, OTS 2020

Y2 - 20 April 2020 through 23 April 2020

ER -

Pretreatment prediction of neoadjuvant chemotherapy response in HER-2 positive breast cancer patients using diffuse optical tomography imaging

Abstract

Conference

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this